Weekly Spotlight - 14.11.24

Community

We want to hear your story!

Fill in the form to share your experiences and any challenges you’ve faced living with your condition, for a chance to be featured in one of our weekly newsletters!

In the News

AskBio's AB-1003 Gains FDA Designations for Muscular Dystrophy Treatment

AskBio's AB-1003 has received FDA designations for treating limb-girdle muscular dystrophy type 2I/R9, a rare disease affecting children. This recognition highlights the urgent need for new therapies. AskBio's ongoing trials aim to provide hope and potential treatment for those affected by this debilitating condition.

Woman Finds Love on Dating App for Disabled After a Dare

Tina Fegley, a woman with muscular dystrophy, found love on Dateability, a dating app for the disabled. Despite initial hesitations, she connected with Tyler Waldman, who has epilepsy. Their shared interests in food and movies led to a blossoming relationship, highlighting the app's positive impact.

Coping with Grief: Navigating Life with Limb-Girdle Muscular Dystrophy

Patrick Moeschen explores coping with grief while living with limb-girdle muscular dystrophy (LGMD). He contrasts the Kübler-Ross model with the dual process model, which resonates more with his experience. This model helps him balance loss-oriented and restorative thinking, fostering patience and perseverance amidst ongoing challenges.

ATA-200 Gene Therapy for LGMD2C/R5 Cleared by FDA

The FDA has approved Atamyo Therapeutics' gene therapy, ATA-200, for clinical trials in the US, targeting Limb-Girdle Muscular Dystrophy Type 2C/R5. This therapy offers hope for children affected by this debilitating condition. The trial, supported by The Dion Foundation, aims to improve patients' quality of life.